Navigation Links
A North American first at the Montreal Heart Institute could help treat thousands of Canadians
Date:2/24/2011

Montreal, February 24, 2011 The interventional cardiology team at the Montreal Heart Institute (MHI) recently began patient enrolment for a new device, the Neovasc ReducerTM, designed to treat patients suffering from refractory angina. The treatment method is a first in North America and is being conducted as part of an international study, the COSIRA trial. This innovative treatment is promising for thousands of Canadians disabled by refractory angina and who lack alternatives for relieving their symptoms and improving their quality of life.

Developed in Canada by Neovasc Inc. (TSX Venture: NVC), the Reducer is implanted in the coronary sinus vein using minimally invasive techniques. Placement of the device is performed using a procedure that is similar to implanting a coronary stent and takes approximately 20 minutes. The Reducer is designed to establish a permanent and controlled narrowing of the coronary sinus, which is a new technique to provide relief of refractory angina symptoms by altering blood flow in the coronary sinus and thereby increasing perfusion of oxygenated blood to certain areas of the heart muscle that receive an inadequate supply of oxygen. Patients are discharged within 24 hours after the intervention.

This landmark procedure was carried out by a MHI multidisciplinary team composed of Drs. Marc Jolicoeur, Serge Doucet and Jean-Franois Tanguay, interventional cardiologists, as well as Dr. Raymond Cartier, heart surgeon. "All the initial cases have gone very well and we are optimistic that the long term results of the procedure will be favourable" says Dr. Marc Jolicoeur who is also assistant professor in the faculty of medicine at the Universit de Montral. "This new method to treat refractory angina safely provides care for patients who cannot be helped with conventional drug, catheter or surgical therapy."

The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients. The primary endpoint is efficacy in reducing angina symptoms after six months. In addition to the Montreal Heart Institute, the COSIRA trial is also enrolling patients at the University of Ottawa Heart Institute, the Antwerp Cardiovascular Institute and Ziekenhuis Oost-Linburg Hospital in Belgium; and Ultrecht Medical Center in the Netherlands. Additional sites are expected to join the trial in the coming months.

Results from the initial first-in-man clinical trial of the Reducer were presented at the American College of Cardiology 2010 annual meeting. The data showed that three years after implantation of the Reducer, the product remained safe and the majority of the 15 patients treated continued to show measurable improvement in angina symptoms.

About refractory angina

Refractory angina is a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle. It currently affects over two million patients worldwide, who typically lead severely restricted lives and current treatment options are limited. The incidence of refractory angina is currently growing as better treatments for coronary artery disease reduce mortality and increase number of patients with advanced disease.


'/>"/>

Contact: Julie Chevrette
julie.chevrette@icm-mhi.org
514-376-3330 x2641
Montreal Heart Institute
Source:Eurekalert

Related medicine news :

1. Toys"R"Us, Inc. Expands its Support of Autism Speaks Throughout North America
2. Alexza and Biovail Form Collaboration to Develop and Commercialize AZ-004 (Staccato(R) Loxapine) in North America
3. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
4. Sleep HealthCenters to Sponsor North East Sleep Society 2010
5. Lafarge North America Recognized by IBI and NBCH for Health & Productivity Leadership
6. Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region
7. St. Josephs Hospital-North Opens in North Tampa
8. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
9. Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery
10. Warning: Immigrating to North America may foster smoking in children
11. Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Knee and Hip Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... to the military at the same time by providing Prehospital Trauma Life Support ... PHTLS is the world’s premier prehospital trauma education developed in cooperation with the ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... from third world countries to hospitals in the United States, it’s a threat ... on the current obstacles facing infection prevention and offers strategies for the healthcare ...
(Date:3/24/2017)... ... , ... The Radiology Business Management Association (RBMA) has named the ... their 12th year, are among the most prestigious in radiology marketing because a panel ... retooled to recognize achievements in both large budget (over $5,000) and small budget (under ...
(Date:3/24/2017)... ... ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the opening ... is the group’s 7th location in San Antonio and 23rd in Texas. Dr. ... from the clinic, which opened March 22, 2017. , The team of ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek Insurance Agencies, a Detroit ... business owners across eastern Michigan, is connecting with the Oxford/Orion FISH Food Pantry ... , The Oxford/Orion FISH Food Pantry works to ensure homeless, hungry, and underprivileged ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017 Abdominal Aortic Aneurysm Repair Devices Market was valued at $1,844 ... a CAGR of 5.1% from 2016 to 2022. The endovascular stent graft system segment ... during the study period. Continue Reading ... ... ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... 2022" report to their offering. ... The global wound care market was worth $24,482.9 million in ... during 2016-2022 Among the various wound care products type, the ... market in 2015. Among the various applications, surgical wound segment held the ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
Breaking Medicine Technology: